Britain’s biggest drugmaker’s latest acquisition will help it to develop new radiotherapy treatments
Business live – latest updates
Britain’s biggest drugmaker, AstraZeneca, is to buy a Canadian cancer specialist focused on next-generation treatments for $2.4bn (£1.9bn), the latest in a string of acquisitions made to strengthen its portfolio of new medicines.
The Anglo-Swedish company struck an agreement to acquire Fusion Pharmaceuticals, which is developing next-generation radioconjugates that offer an alternative to chemotherapy and radiotherapy. It has emerged as a new type of cancer treatment in recent years, and delivers a radioactive isotope directly to cancer cells through precise targeting using molecules such as antibodies, peptides or small molecules.
About Author
More Stories
Virologist Wendy Barclay: ‘Wild avian viruses are mixing up their genetics all the time. It’s like viral sex on steroids’
Microsoft unveils chip it says could bring quantum computing within years
‘It would be seen as political’: why the Royal Society is torn over Elon Musk